The week in pharma: action, reaction and insight – week to September 9

By Barbara Obstoj-Cardwell. Managing editor

Last week’s important news kicked off on Tuesday, when US biotech Sarepta Therapeutics got back on track with the development of its Duchenne muscular dystrophy (DMD) candidate SRP-5051 as the US Food and Drug Administration lifted its clinical hold on US clinical trials. There was more good news, this time for Amylyx, as an FDA advisory committee last Wednesday unexpectedly voted in favor of granting approval for its amyotrophic lateral sclerosis candidate AMX0035. Also of note, US biotech Iveric Bio raised its market capitalization by a third, after it announced positive Phase III data for its ophthalmic candidate Zimura. Swiss pharma giant Roche announced it was acquiring USA-based Good Therapeutics for $250 million. Additionally last week, Swiss firm Basilea Pharmaceutica entered into an asset purchase agreement with Nodus Oncology for its PARG inhibitor program,

Sarepta SRP-5051 clinical hold lifted; trial on track for year-end enrollment